,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31
,Cumulative Foreign Currency Translation Adjustments,Cumulative Foreign Currency Translation Adjustments,Net Actuarial Losses and Prior Service Costs and Credits,Net Actuarial Losses and Prior Service Costs and Credits,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Unrealized Gains on Marketable Equity Securities,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges,Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
(in millions),2014,2013,2014,2013,2014,2013,2014,2013
"Balance at December 31, 2013 and 2012",(718),(79),(1312),(3596),13,31,5,50
Separation of AbbVie (a),—,(307),—,1451,—,—,—,9
Other comprehensive income before reclassifications,62,(391),—,(69),1,7,(1),(18)
Amounts reclassified from accumulated other comprehensive income (a),—,—,16,28,(1),(6),1,(3)
Net current period comprehensive income from continuing operations,62,(391),16,(41),—,1,—,(21)
Balance at March 31,(656),(777),(1296),(2186),13,32,5,38